Featured Research

from universities, journals, and other organizations

New drug doesn't improve disability among stroke patients, researchers find

Date:
February 3, 2012
Source:
American Heart Association
Summary:
A new drug that showed promise in animal studies and an early clinical trial didn't improve disability among stroke patients, according to new research.

A new drug that showed promise in animal studies and an early clinical trial didn't improve disability among stroke patients, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

After a stroke and other types of brain damage, the brain naturally produces more granulocyte colony stimulating factor (G-CSF). The protein can prevent further cell injury by protecting nerve cells and boosting blood vessel growth.

The new drug, AX200, is a manufactured form of G-CSF.

Ninety days after treatment, patients receiving AX200 or a placebo both scored a three on the 0-6 modified Rankin scale, a common test for stroke-related disability.

In a secondary analysis, also at day 90, researchers assessed patients with the National Institutes of Health Stroke Scale. The difference between the drug and placebo was less than half a point (8.88 on AX200 vs. 8.45 on placebo), which was statistically insignificant.

"These top line results are disappointing and unexpected to us because AX200 showed signs of efficacy in a previous clinical trial with a limited number of patients, as well as in numerous animal studies," said Bernd Ringelstein, M.D., lead author of the study and Professor of Neurology at the University of Mόnster, Germany.

"At this time, we cannot speculate about their implications, but our current conclusion is that we were not able to show efficacy for AX200 as a treatment for acute ischemic stroke. We will have to analyze the complete data set in order to fully understand these results."

The study was conducted between August 2009 and November 2011 on 328 patients at 78 stroke treatment centers in eight European countries. The average age of the patients was 69 years and 52 percent were male.

Continuous intravenous infusion of AX200 began within nine hours of first symptoms and lasted for three days. Neither patients nor researchers knew which participants randomly received the drug or placebo.

In the United States, stroke is the No. 4 killer and a primary cause of long-term disability among adults. The most common type, ischemic stroke, is caused by a blocked blood vessel to the brain.

Stroke warning signs are:

  • Sudden numbness or weakness of the face, arm or leg, especially on one side of the body
  • Sudden confusion, trouble speaking or understanding
  • Sudden trouble seeing in one or both eyes
  • Sudden trouble walking, dizziness, loss of balance or coordination
  • Sudden severe headache with no known cause

If any of the symptoms occur, call 9-1-1 immediately, the American Stroke Association advises.

Co-authors are Vincent Thjis, M.D., Ph.D.; Angel Chamorro, M.D.; Martin Grond, M.D., Ph.D.; Jeffrey Saver, M.D.; Bo Norrving, M.D.; and Franz Aichner, M.D.

SYGNIS Bioscience funded the study.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "New drug doesn't improve disability among stroke patients, researchers find." ScienceDaily. ScienceDaily, 3 February 2012. <www.sciencedaily.com/releases/2012/02/120203113322.htm>.
American Heart Association. (2012, February 3). New drug doesn't improve disability among stroke patients, researchers find. ScienceDaily. Retrieved April 16, 2014 from www.sciencedaily.com/releases/2012/02/120203113322.htm
American Heart Association. "New drug doesn't improve disability among stroke patients, researchers find." ScienceDaily. www.sciencedaily.com/releases/2012/02/120203113322.htm (accessed April 16, 2014).

Share This



More Mind & Brain News

Wednesday, April 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Cognitive Function: Is It All Downhill From Age 24?

Cognitive Function: Is It All Downhill From Age 24?

Newsy (Apr. 15, 2014) — A new study out of Canada says cognitive motor performance begins deteriorating around age 24. Video provided by Newsy
Powered by NewsLook.com
App Fights Jet Lag With The Power Of Math

App Fights Jet Lag With The Power Of Math

Newsy (Apr. 13, 2014) — Researchers at the University of Michigan have designed an app to fight jet lag by adjusting your body's light intake. Video provided by Newsy
Powered by NewsLook.com
Treatment Gaps Endangering Cops, Mentally Ill

Treatment Gaps Endangering Cops, Mentally Ill

AP (Apr. 10, 2014) — As states slash funding for mental health services, police officers are interacting more than ever with people suffering from schizophrenia and other serious disorders of the mind. The consequences can be deadly. (April 10) Video provided by AP
Powered by NewsLook.com
Teen Drinking Rates Linked To Alcohol Mentions In Pop Music

Teen Drinking Rates Linked To Alcohol Mentions In Pop Music

Newsy (Apr. 9, 2014) — A University of Pittsburgh study found pop music that mentions alcohol is linked to higher drinking rates among teens. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins